TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35946416
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + COPD Education (COPD‐ED)
Study: 35946416
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + Attention Control (AC)
Study: 32580188
Drug: Roxadustat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (50 mg, n = 49; 70 mg, n = 50)
Study: 35491524
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg with exenatide-matched placebo
Study: 35134184
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice daily 10 µg with dapagliflozin-matched placebo
Study: 33819172
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (testing for STIs and providing information on treatment facilities)
Study: 33143690
Drug: Quadrivalent HPV6/11/16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV6/11/16/18 vaccine (vaccinated group)
Study: 35807803
Drug: Experimental milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental milk-based formula (EF) containing five HMOs (5.75 g/L; 2′‐FL, 3‐FL, LNT, 3′‐SL and 6′‐SL)
Study: 35595781
Drug: Rivaroxaban (factor-Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (factor-Xa inhibitor)
Study: 33491327
Drug: Pseudoephedrine 120
Normalized name: CTM 8/PSEUDOEPHEDRINE 120MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D)
Study: 35412603
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis (JE) vaccine
Study: 35796651
Drug: Sitagliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin plus saline infusion
Study: 35796651
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment + GIP(3‐30)NH2
Study: 32940683
Drug: Preparation for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation for dialysis
Study: 32940683
Drug: Preparation for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation for conservative care
Study: 35095084
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with ambrisentan and tadalafil
Study: 36050542
Drug: As B
Normalized name: Octaplas B
Approvals — FDA: no, EMA: no, PMDA: no
Description: As B but with additional telephone follow-up once weekly for 6 weeks
Study: 32897344
Drug: Out-of-hospital tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group)
Study: 32897344
Drug: Out-of-hospital tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group)
Study: 32323192
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily (OD) or 15 mg OD if creatinine clearance was 30-49 mL/min
Study: 32323192
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg and 20 mg OD dosages
Study: 35112328
Drug: LY01008 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY01008 (3 mg/kg)
Study: 33397855
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml, administered every 15 days for 3 months (Group A)
Study: 33397855
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml plus oral colchicine 0.5mg twice daily for 3 months (Group B)
Study: 32724076
Drug: Sitagliptin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin therapy for 12 months
Study: 35935797
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) in group B
Study: 35935797
Drug: Flupentixol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol and melitracen (FM) + acid-suppressive therapy (AST) in group B
Study: 35935797
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) in group E
Study: 35935797
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists (H2RAs) in group D
Study: 35935797
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists (H2RAs) in group A
Study: 35935797
Drug: Acid-suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-suppressive therapy (AST) in group C
Study: 35722182
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg daily for 12 weeks
Study: 34511288
Drug: Manual control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual control of oxygen titration
Study: 34077887
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g EPA + 1.0 g DHA daily (n = 14)
Study: 34077887
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil daily (n = 18)
Study: 33649058
Drug: Methoxyflurane administered
Normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxyflurane administered by inhalation
Study: 33649058
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Methoxyflurane and Morphine)
Study: 32195952
Drug: Massage chair
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage chair therapy
Study: 616631332
Drug: Actual lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual lithium plasma concentrations in treatment arm
Study: 34536349
Drug: BBIBP-CorV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBIBP-CorV vaccine (2 ?g, 4 ?g, or 8 ?g)
Study: 32899074
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of intravenous dexamethasone
Study: 32899074
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of intravenous dexamethasone
Study: 32899074
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of intravenous dexamethasone
Study: 36109038
Drug: MBEC-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBEC-guided antibiotic regimen
Study: 32667729
Drug: Diuretic monotherapy
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic monotherapy
Study: 35954320
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (treatment group)
Study: 35954320
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (treatment group)
Study: 33210509
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of somatostatin analogues and glucocorticoids in high risk group (25 patients)
Study: 33647900
Drug: Serotonin (5-HT)
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin (5-HT) agonistic drugs
Study: 33647900
Drug: Noradrenaline (NA)
Normalized name: noradrenaline hydrochloride
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noradrenaline (NA) agonistic drugs
Study: 33647900
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DA) agonistic drugs
Study: 32928167
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in addition to a diet and lifestyle intervention
Study: 36149885
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2.5 mg of letrozole and 50 mg of clomiphene citrate (CC)
Study: 36149885
Drug: Letrozole alone
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole alone (2.5 mg)
Study: 34049171
Drug: Sulfurous-arsenical-ferruginous thermal
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfurous-arsenical-ferruginous thermal water inhalation (hot humid air and aerosol)
Study: 34049171
Drug: Combined inhalation
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inhalation and nasal irrigation of sulfurous-arsenical-ferruginous thermal water
Study: 34119901
Drug: Autologous mesenchymal
Normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous mesenchymal stem cell therapy (MSC)
Study: 34119901
Drug: Second course
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second course of MSC therapy
Study: 34119901
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with AEDs
Study: 33406269
Drug: Benzoate (250-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoate (250-1500 mg/d)
Study: 33567390
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments for BED
Study: 32438245
Drug: VAC +
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC + ITM (MLV-vaccine and ITM - Multimin®90 subcutaneously)
Study: 32438245
Drug: VAC +
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC + SAL (MLV-vaccine and saline)
Study: 33092805
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive intraoperative goal-directed therapy (GDT)
Study: 35709823
Drug: Short-term anti-TNF
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term anti-TNF therapy with surgical closure
Study: 32593253
Drug: Inactive vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive vitamin D treatment maintaining levels >34.3 ng/ml for 12 months
Study: 32593253
Drug: Inactive vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive vitamin D treatment
Study: 32593253
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment according to recommendations of the Russian Association of Endocrinologists
Study: 32310005
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (performed at least twice within 6 weeks)
Study: 32294561
Drug: IncobotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA treatment
Study: 36434687
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) for 20 min per session, 6 sessions total, once every two days.
Study: 36180142
Drug: Pilates method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates method (PM) protocol, 16 sessions, twice a week (n=33)
Study: 33737427
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment without Pozzi tenaculum forceps during IUI
Study: 33737427
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment with Pozzi tenaculum forceps during IUI
Study: 35218680
Drug: Intralesional platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional platelet-rich plasma (PRP) injections
Study: 35218680
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (TA) injections
Study: 32715653
Drug: Pharmacist-managed dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-managed dosing algorithm for darbepoetin alfa (DA) and iron sucrose
Study: 34403548
Drug: 4 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 µg/kg oral clonidine
Study: 34403548
Drug: 2 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 µg/kg intranasal dexmedetomidine
Study: 32228512
Drug: gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine + nab-paclitaxel (1000 mg/m2 gemcitabine + 125 mg/m2 nab-paclitaxel)
Study: 32228512
Drug: gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine alone (1000 mg/m2)
Study: 38279662
Drug: MDMA 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 1.5 mg/kg
Study: 35155865
Drug: Steroid avoidance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid avoidance protocol (tacrolimus/MMF/antithymocyte globulin [ATG] induction)
Study: 35155865
Drug: Steroid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid maintenance protocol (tacrolimus/MMF/prednisolone/basiliximab-induction)
Study: 32535191
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning algorithm for automated grading of CD ulcers on capsule endoscopy images
Study: 32535191
Drug: Consensus reading
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consensus reading by 3 capsule readers
Study: 39529175
Drug: Sobriety Treatment
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (SOBRIETE) - BROWN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sobriety Treatment and Recovery Teams (START)
Study: 34236624
Drug: Various therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapies (pharmacologic, electromagnetic, mechanical, sensory, regenerative)
Study: 34236624
Drug: Precision medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision medicine approach
Study: 35347164
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain rye/rye bran (485 g daily for 6 weeks)
Study: 35347164
Drug: Refined wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined wheat (fiber supplemented, 485 g daily for 6 weeks)
Study: 33607357
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg/day for 8 weeks)
Study: 33395586
Drug: Rosa damascene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosa damascene essence 40% in distilled water inhalation for three consecutive nights from 22:00 to 06:00
Study: 33395586
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water inhalation as placebo for three consecutive nights from 22:00 to 06:00
Study: 35606864
Drug: Rosa canina
Normalized name: ROSA CANINA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosa canina L. syrup + methylphenidate (MP)
Study: 35606864
Drug: Polyherbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyherbal formulation (PHF) syrup + methylphenidate (MP)
Study: 34921679
Drug: Test cream
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test cream containing ceramides, triglycerides, and cholesterol in a multivesicular emulsion
Study: 34921679
Drug: Test cream
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test cream
Study: 34921679
Drug: Reference emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference emollient cream
Study: 35022320
Drug: HCQ 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ 600 mg po bid with D+T (dabrafenib 150 mg bid and trametinib 2 mg qd)
Study: 35853600
Drug: Performance feedback
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance feedback intervention (introductory training module, weekly electronic 'Quick Tips', and 3 individualized performance feedback reports)
Study: 32860991
Drug: Sprifermin (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin (highest dose)
Study: 36056419
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg body weight) in addition to the standard of care
Study: 33871742
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication management
Study: 35775704
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (dl‐PDT)
Study: 34479508
Drug: Reconsolidation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconsolidation Therapy (RT)
Study: 32925713
Drug: Yangyin Shuxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangyin Shuxin Decoction combined with standard treatment
Study: 33413555
Drug: C‐Mill training
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐Mill training (10 sessions, 1 hour each, twice per week for 5 weeks)
Study: 34610049
Drug: Screened for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screened for AF using a continuous-recording ECG patch worn for two weeks and 2 occasions, 3 months apart.
Study: 34836902
Drug: Usual occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual occupational therapy
Study: 33781780
Drug: Continuous chest
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chest wall vibration with concurrent aerobic training
Study: 34843312
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment (IG)
Study: 33580603
Drug: KRP-116D (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRP-116D (50% dimethyl sulfoxide solution)
Study: 33513485
Drug: CYP2D6 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6 genotype and functional status treatment
Study: 33513485
Drug: Standard psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychotropic therapy
Study: 34113353
Drug: estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol (E2) patch
Study: 34113353
Drug: transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal placebo
Study: 35614185
Drug: Chitin-glucan (CG)
Normalized name: Chitin
DrugBank: Chitin (DB15142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitin-glucan (CG) supplementation (4.5 g daily)
Study: 34089219
Drug: VAIA III
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAIA III plus optional maintenance therapy (MT) in CWS-2002P
Study: 34522175
Drug: Short-axis hydrodissection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-axis hydrodissection (5 mL normal saline per session)
Study: 34522175
Drug: Long-axis hydrodissection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-axis hydrodissection (5 mL normal saline per session)
Study: 36457653
Drug: Citrus aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus aurantium essential oil (2 drops, twice a day, for four consecutive days a week, for four weeks)
Study: 32791810
Drug: Cipterbin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipterbin (4 mg/kg loading dose and 2 mg/kg maintenance dose each week, IV) combined with vinorelbine (25 mg/m(2) on days 1,8 and 15 of each 28 days, IV)
Study: 32791810
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m(2) on days 1,8 and 15 of each 28 days, IV)
Study: 36222438
Drug: ELOM-080 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELOM-080 (4 × 1 capsule per day)
Study: 35411076
Drug: AAV8‐VRC07 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV8‐VRC07 (5 × 10^10, 5 × 10^11, and 2.5 × 10^12 vector genomes per kilogram by intramuscular injection)
Study: 32673048
Drug: Alcohol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (target blood alcohol concentration of .08 g%)
Study: 34668982
Drug: Carfilzomib (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (36 mg/m2) administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle
Study: 33733720
Drug: Perineural corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural corticosteroid injection (Methylprednisolone acetate 40 mg and 1 mL of 1% trimecaine hydrochloride injected next to the median nerve)
Study: 33733720
Drug: Peritendinous corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritendinous corticosteroid injection (Methylprednisolone acetate 40 mg and 1 mL of 1% trimecaine hydrochloride injected among flexor tendons away from the nerve)